Kancera Targets COVID-19 With Fractalkine Inhibitor
CEO Hopes Phase II Trial Will Advance KAND567
Executive Summary
Sweden-based Kancera hopes to advance its investigative anti-inflammation drug in a Phase II trial to treat severe COVID-19 patients and then build its applications from there.